A risk index for early node-negative breast cancer
Open Access
- 11 April 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 93 (5), 564-571
- https://doi.org/10.1002/bjs.5207
Abstract
Background: This study compared the application of the St Gallen 2001 classification with a risk index developed at the New South Wales Breast Cancer Institute (BCI Index) for women with node-negative breast cancer treated without adjuvant systemic therapy. Methods: The BCI risk categories were constructed by identifying combinations of prognostic indicators that produced homogeneous low-, intermediate- and high-risk groups using the same variables as in the St Gallen classification. Results: The BCI low-risk category consisted of women aged 35 years or more with a grade 1 oestrogen receptor (ER)-positive tumour 20 mm or less in diameter, or with a grade 2 ER-positive tumour of 15 mm or less. This category constituted 40·1 per cent of patients, with a 10-year distant relapse-free survival (DRFS) rate of 97·2 per cent. The BCI intermediate-risk category included women aged 35 years or more with a grade 2 ER-positive tumour of diameter 16–20 mm, or a grade 1 or 2 ER-negative tumour measuring 15 mm or less, and comprised 12·1 per cent of the women, with a 10-year DRFS rate of 88 per cent. The high-risk category comprised 47·7 per cent of women, with a 10-year DRFS rate of 68·4 per cent. Conclusion: If confirmed in other data sets, the BCI Index may be used to identify women at low risk of distant relapse (2·8 per cent at 10 years) who are unlikely to benefit from adjuvant systemic therapy, and women at intermediate risk of distant relapse (12 per cent at 10 years) in whom the benefit of adjuvant systemic therapy is small.Funding Information
- New South Wales Department of Health
This publication has 17 references indexed in Scilit:
- The 1998 St. Gallen's Consensus Conference: an AssessmentJNCI Journal of the National Cancer Institute, 1998
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up.Journal of Clinical Oncology, 1995
- Factors Influencing Survival and Prognosis in Early Breast Carcinoma (T1N0M0–T1N1M0): Assessment of 644 Patients with Median Follow-up of 18 YearsSurgical Clinics of North America, 1990
- Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years.Journal of Clinical Oncology, 1989
- A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma.Journal of Clinical Oncology, 1989
- The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO ('Nolvadex') trialBritish Journal of Cancer, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Histological Grading and Prognosis in Breast CancerBritish Journal of Cancer, 1957